rtTA(1st Gen), rtTA -advanced (2nd Gen)and Tet-On(3Gen)

1. rtTA (Original 1st Generation)
• Structure: This was the original fusion of a reverse Tet repressor (rTetR) and the full-length VP16 activation domain from Herpes Simplex Virus.
• Mutations: Contains 4 amino acid changes relative to wild-type TetR (E71K, D95N, L101S, G102D).
• Limitations:
o Genetic Instability: The gene sequence utilized bacterial codons and contained cryptic splice sites, leading to unstable expression in some mammalian cells.
o Toxicity: The full-length VP16 domain is known to sequester cellular transcription factors (“squelching”), which can be toxic to cells.
o Leakiness: It retains significant affinity for the promoter even without Dox, causing high background expression.
2. rtTA-Advanced (2nd Generation)
• Also known as: rtTA2^S-M2
• Structure: This variant represented a major structural overhaul. It replaced the toxic full-length VP16 with a 3x Minimal VP16 domain (three repeats of a small activation motif). The gene sequence was also completely synthetic, optimized for human codon usage, and stripped of cryptic splice sites.
• Mutations: It utilizes the “M2” set of mutations in the DNA binding domain (S12G, E19G, A56P, D148E, H179R).
• Improvements:
o Stability: The synthetic gene and removed splice sites made it much more stable in mammalian cells.
o Reduced Toxicity: The 3x Minimal VP16 domain eliminated the “squelching” toxicity issues.
o Better Specificity: It functioned well with the improved TRE-Tight promoter to reduce background leak.
3. Tet-On 3G (3rd Generation)
• Also known as: rtTA-V16 (derived from the S2 lineage, not M2)
• Structure: It retains the optimized 3x Minimal VP16 activation domain and synthetic human codon structure of the 2nd generation but introduces a completely new set of mutations in the TetR domain to maximize sensitivity.
• Mutations: It contains 9 mutations relative to wild-type (V9I, E19G, A56P, F67S, F86Y, D148E, R171K, H179R, A209T).
• Key Advantage (Sensitivity):
o Tet-On 3G is 100-fold more sensitive to Doxycycline than the original rtTA and significantly more sensitive than rtTA-Advanced.
o It is designed to pair with the TRE3G promoter, which has point mutations reducing background noise to near-zero levels.